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doi:10.1016/j.ejvs.2009.02.002Abstract Background: Knowledge in the aetiopathogeny of aortic disease helps to character-
ise aortic lesions better and determine the risk of evolution and therapeutic strategies as well.
This article focusses on aneurysms and dissections, and excludes causes related to infection,
systemic inflammatory diseases and trauma.
Methods and results: The biomedical literature of the past 10 years has been reviewed here.
Aortic diseases are heterogeneous along the aorta as far as their genetic determinants, contri-
bution of smooth muscle cells, inflammation and thrombus formation are concerned. Degrada-
tion of extracellular matrix by proteases causing aortic disease is a ‘terminal’ event,
modulated by genetic background, haemodynamic strain, cellular events and thrombus forma-
tion. New genetic determinants of aortic disease have been identified. Proteases degrading the
aortic wall are derived from a variety of cell types in addition to macrophages, including
neutrophils on the luminal thrombus, mesenchymal and endothelial cells in the wall. Smooth
muscle cells contribute to aortic wall homeostasis against inflammation and proteolysis. The
degradation of the wall is followed by, or paralleled with, a failure of aortic reconstruction.
Conclusions: Aortic diseases are diverse, and involve a multiplicity of biological systems in the
vascular wall and at the interface with blood. Future research needs to unravel distinct
cellular and molecular mechanisms causing the clinical events, in particular, dissection,
expansion of already formed aneurysms and rupture.
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532 E. Allaire et al.The aorta is made up of an abundant extracellular matrix itself is characterised by aortic stenoses, in sharp contrast to
6(ECM) which is responsible for its resistance to arterial flow
and pressure. The structural and functional consequences of
the weakening of the aortic wall are dilatation, tortuosity,
dissection and rupture. Aortic diseases are differently
distributed along the aorta, according to their aetiopathog-
eny. The frequency of abdominal aortic aneurysms (AAAs) is
more than 3 times higher than that of thoracic and dissection
aneurysms.1,2 New insights in the role of gene mutations and
factors determining the heterogeneity of diseases along the
aorta have changed our understanding of the determinants
of aortic diseases. Identification of multiple sources of
proteases degrading aortic ECM and the role of vascular
smoothmuscle cells (VSMCs) and endothelial cells provide us
with different mechanisms accounting for the multiple
aspects of aortic diseases.Genetic Determinants of Aortic Disease: the
Example of Marfan Syndrome
The observation that different individuals in a family have
have an aortic disease has prompted the idea that aortic
aneurysms and dissections may have strong genetic deter-
minants. A family history is documented in 20% of the cases
of thoracic aneurysms3 and AAAs.1 Aortic diseases can be
associated with multiple characteristic abnormalities in
other tissues in a syndromic pattern.4 There is a gradation
of severity of the clinical course of thoracic and abdominal
aortic diseases, from sporadic to familial and syndromic
cases, with symptoms at younger age, faster aortic dilata-
tion and higher rupture risk in the latter.1,3 Numerous gene
mutations in transgenic mice cause vascular rupture in
utero because of inadequate vasculogenesis. Genetic
syndromes in humans are compatible with embryonic vas-
culogenesis and allow for survival for two decades of life,
although very severe paediatric cases have been reported
as well. In thoracic aneurysms and dissections, mutations
have been identified in genes encoding for ECM proteins,
growth factor receptors and proteins implicated in cell
contraction, resulting in inadequate capability of the aortic
wall to resist haemodynamic strain.5
The Marfan syndrome (MFS) is a prototype for the iden-
tification of gene mutations causing aortic disease.4 It is an
autosomal dominant hereditary disorder affecting skeletal,
ocular and cardiovascular systems.4 Recent advances
provide insights into the mechanisms by which mutation in
a single gene triggers a cascade of molecular, cellular and
tissular alterations which ultimately lead to aortic dilation,
dissection and rupture. MFS is caused by heterozygous
mutations in the gene encoding fibrillin 1, an ECM protein
which serves as a template for elastin microfibril formation.
Aortic and skeletal features of MFS have been reproduced in
mice by mutating the fibrillin 1 gene. Abnormal fibrillin 1
encoded by the mutated allele impairs the formation
of microfibrils by non-mutated fibrillin 1, in a dominant-
negative pattern. In other words, it is a case of heterozygote
disorder in which the function of the normal protein is
altered by the abnormal protein. Aortic manifestations in
MFS are not entirely explained by abnormal elaboration of
the elastin network. Besides, the WilliamseBeuren
syndrome caused by a micro-deletion in the elastin geneMFS. After a cascade of events, fibrillin 1mutation results in
fragmentation of the elastin network by matrix metal-
loproteinases (MMPs) which are up-regulated in humans and
mice with MFS.7,8 Administration of doxycycline, an inhibitor
of MMP, controls aortic expansion and rupture in MFS mice.8
A direct link between fibrillin 1 gene mutation and MMP-
driven proteolysis is suggested by the observation that
mutated fibrillin 1 in MFS has an increased susceptibility to
proteolysis, and that its fragments up-regulate MMP
expression and are powerful chemo-attractants for macro-
phages.4 These data provide a model in which a single initial
genetic defect triggers a cascade of events organised into
a loop which amplifies tissue destruction.
A second mechanism by which fibrillin 1 mutations cause
aortic disease in MFS involves the growth factor/cytokine
transforming growth factor-beta1 (TGF-beta1). TGF-beta1
protein and signalling are increased in cells from human
MFS aortas and in emphysematous lung from fibrillin 1
mutated mice. Enhanced TGF-beta signalling in MFS is
thought to increase VSMC apoptosis and impair aortic
healing because of hyaluronan up-regulation. TGF-beta
signalling is instrumental in aortic dilatation in fibrillin 1
mutated mice, since its blockade, directly by anti-
TGF-beta1 neutralising antibody or indirectly by the
administration of losartan, an angiotensin II type 1 receptor
antagonist, prevents aortic aneurysm formation.9 The
mechanisms by which fibrillin 1 gene mutations up-regulate
TGF-beta1 signalling are not fully understood. The fibrillin
family is closely related to the latent-TGF-beta-binding
protein (LTBP) family, a reservoir of latent (inactive)
TGF-beta1, regulating its activation. There are indications
that upon mutation, abnormal fibrillin 1 has a low affinity
for latent-TGF-beta1 and thus releases excessive amounts.
More than 600 mutations in the fibrillin 1 gene have been
identified not only in MFS patients, but also in those with
isolated cranial manifestations without aortic disease, or
with isolated aortic disease. These mutations affect various
functional domains of the fibrillin 1 protein and have
various biological consequences.4 Mutations in genes other
than fibrillin 1, encoding proteins which also directly or
indirectly regulate TGF-beta activity and signalling, have
been identified in patients with aortic disease and/or MFS
or related disorders.4 These mutations result in an increase
in TGF-beta1 signalling rather than a loss of function.
Mutations in TGF-beta receptors 1 and 2 cause LoyeseDietz
syndrome, in which the ascending aorta dilates to aneu-
rysmal size, with tortuosities, ruptures and dissections.10
Cases of non-syndromic familial thoracic aneurysms and
dissections have also been associated with mutations in
TGF-beta receptors 1 and 2. Mutations in the genes
encoding fibullin 1 and 4, which regulate TGF-beta activa-
tion4 result in enlargement of the ascending aorta in mice.
Mutations in the glucose transporter GLUT10 causing up-
regulation of TGF-beta1 are associated with tortuosity of
the aorta in mice and humans.11 These data establish that
excessive TGF-beta signalling may result from mutations of
a variety of proteins and is linked to thoracic aortic aneu-
rysms and dissections, both syndromic and familial.
Mutations in genes encoding other proteins with no
apparent link to TGF-beta signalling have been identified in
patients with aortic disease. Collagen III mutations cause
New Insight in Aetiopathogenesis 533vascular type IV EhlerseDanlos syndrome.Mutations of genes
encoding contractile proteins in VSMC, like the ACTA2 gene
encoding smooth muscle cell alpha-actin12 and the MYH11
gene encoding myosin heavy chain13 are responsible for
familial forms of thoracic aneurysms. Mutations in myosin
heavy chain are associated with an up-regulation of pro-
inflammatory angiotensin II in the aneurysmal wall and of
insulin growth factor. This fact suggests that altered
contractile properties may not be the mechanism by which
aneurysms form after mutations of myosin heavy chain, in
the same manner that a defect in elastin may not be the
direct cause of aortic disease in MFS. Rather, despite the
diversity of genetic defects, aortic diseases develop through
a common pathway represented by elastin destruction by
some level of proteolysis, cystic medial necrosis and altered
biomechanical properties. In favour of this view, in patients
with an aneurysm of the ascending aorta, platelets and
prothrombin are activated in proportion to the aortic diam-
eter, independently of the aetiology of aortic dilation, that
is, in MFS, aortic valve bicuspidy and degenerative disease.14thrombus
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Figure 1 Proposed mechanisms for destruction and recon-
struction in the aortic wall. Different sources of proteases. (1)
The interplay between lymphocytes and macrophages regu-
lates production of proteases (P). (2) Neutrophils adsorbed at
the surface of the luminal thrombus liberate proteases which
diffuse centrifugally to the aneurysmal wall, causing ECM
destruction and VSMC death (anoı¨kis). (3) Angiogenesis in the
adventitia, spreading to the media, causes influx of leukocytes
and concentrates proteases. Fibroblasts in the adventitia may
also produce proteases. The three mechanisms may not be
active simultaneously in a same type of lesion at the same time
of its evolution. (4) VSMCs in the media produce inhibitors of
proteases, and TGF-beta1 which, under particular circum-
stances, triggers ECM production and down-regulates inflam-
mation. (5) Fibroblasts in the adventitia produce ECM.Proteases in Aortic Disease
The spectrum of proteases found in excess in aortic aneu-
rysms and dissections includes MMPs, cathepsins, chymase
and tryptase, neutrophil-derived serine elastase and the
enzymes of the plasmid pathway tPA, uPA and plasmin.
Some of these proteases may be involved in some level of
tissue reconstruction and/or remodelling. However, the
main role assigned to proteolysis in aortic diseases,
particularly in aneurysms, is ECM destruction. This
perception stems from the pioneering work of Dobrin, who
showed that in vitro perfusion of arteries with elastase or
collagenase triggers vessel dilation, elongation and
rupture.15 The instrumental role of proteolysis has been
further documented by Michel and co-workers who devel-
oped a reproducible animal model of AAA by perfusing rat
aortas with elastase in vivo.16 The localisation of the
elastase MMP-12 to residual elastin fragments in the media
of human AAAs provides strong evidence of ECM-targeting
by proteases. In tissues, the proteolytic activity results
from a balance between proteases and their physiologic
inhibitors. TIMP-2, a broad-spectrum MMP inhibitor, and
PAI-1, an inhibitor of tPA and uPA, are less expressed in the
wall of AAAs than in athero-occlusive aortic disease,1 sug-
gesting that ECM destruction is caused by a decrease in
inhibitors in addition to an increase in proteases. The role
of MMPs and enzymes of the plasmin pathway has been
demonstrated using gene and cell transfer to overexpress
TIMP-117 and PAI-1,18 and by PAI-1 gene invalidation,
thereby shifting protease/antiprotease balances.19 The
overexpression of both TIMP-1 and PAI-1 prevents experi-
mental AAA formation and rupture, and preserves elastin in
the media layer by decreasing MMP-9 activity, but through
different mechanisms. TIMP-1 overexpression was shown to
inhibit directly active MMP-9 on gelatin zymograms,17
whereas PAI-1 overexpression blocked the activation of
(inactive) pro-MMP-9 by blocking tPA and uPA.18 Inhibition
of protease expression by gene invalidation has shown that
MMP-3, MMP-9 and MMP-12 drive AAA formation in the
elastase model in mice. As a demonstration of its role,polymorphism in MMP-9 predisposes to AAA in humans.20 At
the level of the thoracic aorta doxycycline, an inhibitor of
MMP-9 synthesis and activity limits dilatation of the
ascending aorta in MFS mice.8 In humans with MFS,
however, levels of MMP-9 and an array of other MMPs in
aneurysms of the ascending aorta are low, questioning the
role of proteases in this setting.
Diverse Sources of Proteases (Fig. 1)
Mononuclear leucocytes
Once the role of proteases is recognised, particularly in
aortic aneurysms, their origin and how their accumulation
in the aortic wall are regulated remain important ques-
tions. The case of the ascending aorta regarding inflam-
mation as a potential source of proteases is complex and
may vary according to its aetiological background. Whether
macrophages infiltrate the ascending aorta of MFS patients
is debatable. In non-MFS patients with disease on the
ascending aorta, T lymphocytes and macrophages have
been observed in type A dissection and aneurysms of mixed
aetiologies.21 In AAAs, the relationship between inflam-
mation and protease expression is more documented than
in diseases of the ascending aortas. Inflammation driven by
auto-immunity has been proposed by Tilson as a mechanism
of tissue destruction in AAAs.22 Activated T and B lympho-
cytes tend to gather in the adventitia in follicular struc-
tures.23 The pharmacological inhibition of c-Jun kinase,
a signalling molecule, causes AAA-regression in a mouse
534 E. Allaire et al.model, while decreasing wall infiltration by macrophages as
well as the aortic MMP-9 content.24 The higher level of
expression of MMP-9 in larger than in smaller AAAs is
concordant with the idea that rupture, inflammation and
proteolytic burden are closely related. These observations
are solid data. However, discriminating the exact role of
proteolysis derived from mononuclear leucocytes in aortic
disease remains difficult. In fact, recent evidence suggests
that mononuclear phagocytes may not be the only cellular
source of proteases, let alone the most significant.Polymorphonuclear neutrophils and thrombus
Michel et al. have shown that the luminal thrombus of AAAs
appears to be a reservoir of proteases delivered by neutro-
phils. It develops over years, but is covered by a thin layer of
fresh fibrin which traps neutrophils.25,26 Its outer aspect is
sometimes separated from the aneurysmal wall by a liquid
where proteases accumulate.25 These data support the view
that neutrophils adsorbed on the thrombus are major sour-
ces of proteases, distributed centrifugally from the
thrombus surface to the wall of AAAs. In addition to
degrading ECM, neutrophil-derived elastase detaches VSMCs
from ECM, causing cell death, a process named anoı¨kis,
thereby contributing to the absence of mesenchymal cell
development in the thrombus.26 In mice, depletion in poly-
morphonuclear prevents formation of AAA after aortic
elastase infusion.27 In type A dissection in humans, plasma
levels of MMP-9 increase as early as 1 h after symptom onset,
suggesting that polymorphonuclear degranulation accounts
for protease release in this acute context.28
Coincident with the work of Michel’s group, Schwe-
denborg and co-workers have documented that the AAA
wall covered by the thrombus is thinner, with fewer
VSMCs and a more severely injured elastin network than
wall areas uncovered by it.29 These data are concordant
with the clinical observations that AAA expansion and risk
of rupture are correlated to thrombus size.30 In chronic
type B dissections of the aorta, presence of a thrombus
in the circulating false lumen is associated with an
increased mortality,31 another indication that the
thrombus modulates evolution of aortic diseases, possibly
by trapping neutrophils which deliver proteases to the
aortic wall.
Mesenchymal cells and micro-vessels
Mesenchymal cells, for example, VSMCs and fibroblasts, are
other potential sources of proteases in aortic disease.
Newman and co-workers have observed that, unlike MMP-3
and MMP-9, the MMP-1 collagenase is co-localised with
mesenchymal cells in AAA wall.32 MT1-MMP, a cell
membrane-bound MMP instrumental in MMP-2 activation, is
localised in VSMCs in AAAs. Mesenchymal cells may be
responsible for the destruction of collagen by producing
and releasing MMP-1 and by contributing to elastin injury
through the activation of MMP-2.
Strikingly, but in line with this view, inflammation (e.g.,
macrophages and T lymphocytes) is not the prominent
feature in rupture edges of AAAs and is less than in non-ruptured areas or walls of the same AAAs. Rather, ruptured
areas present significantly increased amounts of immature
micro-vessels, with an excess of total and activated MMPs33
and with cells presenting an immunostaining pattern sug-
gesting fibroblasts. These data need further confirmation,
but suggest that micro-vessels and fibroblasts are prominent
sources of proteolytic enzymes at sites of rupture in AAAs.
From these observations it appears that aortic lesions
are highly heterogeneous with regards to the source of
proteases. Presence or absence of a luminal thrombus and
formation of rupture modulate the cellular sources of
proteases.
Vascular Smooth Muscle Cells and Aneurysm
Remodelling (Fig. 1)
The outcome of VSMCs in lesions of the ascending aorta is
complex. In (non-atherosclerotic) aneurysms of the
ascending aorta, VSMC density may vary according to
patient’s ageandgender andalso according to theareaof the
aneurysm inwhichquantification is performed.21 Conversely,
depletion of VSMCs in the media is a characteristic of
atherosclerotic aortic aneurysms.1 In AAAs, VSMC death has
often been regarded as a bystander effect of wall destruc-
tion. Accumulating data support the concept that VSMC
disappearance is a permissive factor for AAA formation and
expansion, rather than a bystander event. Not only do VSMCs
decrease at sites of arterial ECM destruction by inflammation
and proteolysis in AAA media, but also in ruptured fibrous
caps of atherosclerotic plaques in the intima. In a rat model
of AAA, we have shown that addition of VSMCs prevents AAA
formation34 and suspends expansion of already formed
AAAs.35 Another group has shown that delivery of bFGF,
a growth factor for VSMCs, prevents formation of experi-
mental AAAs.36 Several mechanisms explain the fact that
addition of VSMCs stops expansion of AAAs. One such mech-
anism is the making of new ECM by VSMCs.35 The other is the
down-regulation of inflammation and proteolysis in the
vicinity of added VSMCs.34,37 VSMCs exert a paracrine effect
that down-regulates effectors of tissue destruction, by
producing TIMPs and TGF-beta1. We have established that
TGF-beta1 overexpression by endovascular gene transfer
stabilises the diameter of expanding AAAs.38
In addition to its impact on inflammation and proteol-
ysis, the decrease in the number of VSMCs in AAAs may alter
the ability of the diseased aorta to respond to radial stress
in an adapted manner. Chronicity and irreversibility of AAAs
are consequences of inadequate responses to injury or
functionally inadequate healing. VSMCs support vessel wall
hypertrophy in response to radial strain in hypertension and
during arterialisation of veins grafted into the arterial
system in bypass surgery.39 VSMCs mechanically stimulated
in vitro produce TGF-beta1, ECM and inhibitors of prote-
olysis, which contribute to increasing artery wall mass.40 In
sharp contrast to VSMCs, macrophages respond to
mechanical stress by producing proteases which degrade
ECM. As a result, the effect of wall stress on VSMC-
depleted, macrophage-infiltrated AAAs may be wall
destruction, rather than a trophic response.
As a consequence of VSMC depletion, the AAA wall tends
to heal in a particular manner. Whereas hypertrophic
New Insight in Aetiopathogenesis 535remodelling in vessels rich in VSMCs is elaborated in the
media and intima, AAAs compensate for atrophy by
increasing thickness of the adventitia, a process governed
by fibroblasts rather than VSMCs. However, in other aetio-
logical backgrounds, the aorta demonstrates robust healing
capacities. Clinicians know how the inner medial flap in
chronic dissections thickens over time. Whether differ-
ences in aortic healing between dissections and AAA are
due to differences at the level of the aortic lesion or to
differences in patient homeostasis remains undefined.
Supporting the latter hypothesis, the poor capabilities of
tissues to heal in patients with AAAs expand beyond the
aorta, as demonstrated by the increased number of aneu-
rysmal degeneration of venous bypasses in patients with
aneurysms.
Topologic Determinants of Aortic Disease
(Table 1)
Heterogeneity of aortic disease along the aorta
The distribution of prevalence and causes of aneurysms
along the aorta are highly heterogeneous. Of the thoracic
aneurysms, 50% are located on the ascending aorta, 10% on
the cross and 40% in the descending aorta.3 There is
a gradient of frequency of identified monogenic defects
associated with aneurysms, from the ascending to the
abdominal segments of the aorta. Atherosclerosis is associ-
ated with aneurysms from the aortic arch to its end, but
spares the ascending aorta, in which aetiopathogenic back-
grounds are haemodynamic factors, aortic valve bicuspidy,
monogenic defects and degeneration. The tropism of
atherosclerotic aneurysms excluding the ascending aorta is
further supported by the observation that smoking and
atherosclerotic plaque burden are correlated with dilatation
of the thoracic aorta stating from the arch, but not of the
ascending aorta. Atherosclerotic aneurysms are at least 3
timesmore frequent in the abdominal than in the descending
thoracic segment of the aorta.
The macroscopic and histological appearance of aneu-
rysms also differs according to their location along the
aorta. The luminal aspect of aneurysms in the ascending
aorta is essentially free from thrombus, in contrast to more
distal aneurysms. The density of VSMCs in the media layer isTable 1 Differences between the ascending and the abdomina
Ascending aorta Abdominal a
Structure
Elastin lamellae e number dec
elastin/collagen e decreased
Embryonic origin
of VSMCs
neurectoderm mesoderm
Shear stress e decreased
Thrombus in aneurysms no yes
VSMCs in aneurysms ? decreasedalso different, with a preserved density in the most dilated
portion of aneurysms of the ascending aorta in patients
with no MFS, and a decreased density in the media of AAAs.
In aneurysms of the ascending aorta with tricuspid aortic
valves, we have observed that VSMC density is decreased
only in the transitional area in comparison with the
maximal dilatation zone.21 In any case, our observation and
reports from others suggest that the media of aneurysms of
the ascending aorta are re-populated by VSMCs, which is
clearly not the case in AAAs.
Lastly, the pattern of micro-vessel infiltration is also
different according to the site and cause of the disease. We
have observed micro-vessels penetrating into the media
layer of aneurysms in the ascending aorta, whereas those in
the media of AAAs are observed only in ruptured areas.21
Others have shown reduction in the number of vasa vasora
in aneurysms of the ascending aorta in patients with
mutations in smooth muscle cell alpha-actin genes, with
possible ischaemia in the media layer. Whether these
differences are determined by differences in the patho-
genic process or in VSMCs and endothelial cell prolifera-
tion/survival according to their localisation along the aorta,
needs to be determined. This topographic heterogeneity
regarding aneurysms suggests that aetiopathogenic deter-
minants are distributed according to gradients along the
aorta.
One first determinant of the heterogeneity of aortic
diseases may be the architecture of the aorta. Wolinsky and
Glagov have proposed the concept of an elastic lamellar
unit as a functional element of the aorta formed by an
elastic lamella and VSMCs, and demonstrated correlations
between blood pressure, aortic diameter and the number
of elastic lamellar units across animal species.41 The
number of elastic lamellae decreases along the aorta,
which also becomes thinner and smaller in diameter. The
elastin to collagen ratio is constant along the aorta, except
in its abdominal segment in which it is decreased. The aorta
in acardiac foetuses does not acquire differentiation of its
structure from cranial to caudal ends, demonstrating the
impact of haemodynamic strain on vascular architecture.
Since a minimal number of elastic lamellae needs to be
injured for aneurysms to form, the reduced number of
elastic lamellae may explain their abdominal tropism.
Haemodynamic strain, which varies along the aorta, may
also determine the topology of aortic diseases. Several factsl aorta
orta Consequences
reased/diameter less provisional ECM
modified biomechanical
properties
differences in responses to TGF-beta
control of inflammation
neutrophils adsoption
and protease release
homeostasis against
inflammation, proteolysis
536 E. Allaire et al.suggest a relationship between strain and aortic disease.
VSMC apoptosis predominates in the convex aspect of the
ascending aorta in patients with bicuspid valves, even in the
absence of an aneurysm.42 The observation that patients
with limb amputation have a higher prevalence of AAA
suggests that asymmetric reflection of the systolic wave
during the cardiac cycle causes injury to aortic ECM.43 Shear
stress and resistive conditions may modulate aneurysm
formation. In rats, a higher shear stress prevents AAA
formation after elastase infusion.44 The protective effect of
shear stress is associated with a shift of the destruction/
reconstruction balance in the aortic wall. Macrophage
infiltration, MMP-9 and pro-inflammatory reactive oxygen
species expression are shut down by shear stress after
elastase infusion, whereas VSMC density and expression of
heme oxygenase 144 are increased. These experimental data
are supported by clinical observations. In humans, a poly-
morphism resulting in a lower level of heme oxygenase
expression is associated with a higher prevalence of AAA.
The occurrence of AAA is higher in patients with peripheral
vascular occlusive disease or spinal cord injury, two condi-
tions in which shear stress is decreased. The lower preva-
lence of aneurysms in the thoracic segment in which flow
resistivity is lower than in the abdominal segment also point
to the role shear stress plays in protecting the thoracic aorta
from inflammation, proteolysis and VSMC death. VSMC
contractile force requires cyclic interactions between
smooth muscle cell alpha-actin (encoded by the ACTA2
gene) and beta-myosin heavy chain (encoded by the MYH11
gene). The association of mutations in these two genes with
familial thoracic aneurysms and dissections,12,13 suggests
that alterations in VSMC contraction predispose one to
disease of the thoracic aorta, which is more mobile during
the cardiac cycle than the abdominal aorta.
Another factor gradated along the aorta is the embry-
onic origin of VSMCs and how they respond to TGF-beta.
VSMCs in the proximal end of the aorta originate predomi-
nantly from the neural crest, whereas more distally, they
are derived from the mesoderm. The VSMC response to
TGF-beta1 varies sharply according to their embryonic
origin. TGF-beta1 potentiates growth and collagen
I production in neural-crest-derived VSMCs (thoracic),
whereas it inhibits growth and has no effect on collagen
I synthesis in VSMCs from mesodermal origin (abdominal).45
Mesodermal VSMCs produce more abundant tropo-elastin
than neural-crest-derived ones. Since VSMCs are key
determinants of aneurysm formation34 and expansion,35,44
differences in their survival, proliferation and ECM
synthesis in response to a growth factor such as TGF-beta1
are expected to modulate aortic response to inflammation
and proteolysis, and haemodynamic strain and be a deter-
minant of the topology of aortic diseases. In return, TGF-
beta1 induced in VSMCs exposed to radial strain modulates
its growth. TGF-beta1 is a potent regulator of inflammation
and proteolysis. Activation of TGF-beta1 signalling seems to
be associated to the dilatation of the proximal aorta in MFS
mice. In contrast, it is closely related to intimal plaque
stability in atherosclerosis, and overexpression of mutated
active TGF-beta1 by endovascular gene therapy powerfully
inhibits growth of already formed AAAs in rats.38 We have
also documented that pharmacological induction of TGF-
beta1 in rat and mouse models of abdominal aneurysmsinhibits aortic dilatation, and decreases MMP expression in
a culture model of human atherosclerotic AAA (manuscript
submitted for publication).
Conclusion
The degradation of ECM by proteases causing aortic disease
is a ‘terminal’ event, determined by the genetic back-
ground, VSMC death and growth, inflammation and
thrombus formation. Aortic diseases are heterogeneous
along the aorta, with regards to their determinants and the
contribution of VSMCs, inflammation and thrombus forma-
tion. The degradation of the wall is followed by, or paral-
leled with, a failure of aortic reconstruction. Future
research needs to unravel the specificities of very different
events, namely diameter and length increase, aortic
rupture and dissection, driven by different cellular and
molecular mechanisms.Acknowledgements
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